Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 177

The DOI matches its Crossref record.

Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technology

Open access
Che, James, Yu, Victor, Dhar, Manjima, Renier, Corinne, Matsumoto, Melissa, Heirich, Kyra, Garon, Edward B., Goldman, Jonathan, Rao, Jianyu, Sledge, George W., Pegram, Mark D., Sheth, Shruti, Jeffrey, Stefanie S., Kulkarni, Rajan P., Sollier, Elodie, Di Carlo, Dino · 2016 · Oncotarget

Abstract

// James Che 1,2 , Victor Yu 1 , Manjima Dhar 1 , Corinne Renier 2,3 , Melissa Matsumoto 1 , Kyra Heirich 3 , Edward B. Garon 4 , Jonathan Goldman 4 , Jianyu Rao 5 , George W. Sledge 6 , Mark D. Pegram 6 , Shruti Sheth 6 , Stefanie S. Jeffrey 3,6 , Rajan P. Kulkarni 1,7 , Elodie Sollier 1,2,3 and Dino Di Carlo 1,8,9 1 Department of Bioengineering, University of California, Los Angeles, California, USA 2 Vortex Biosciences, Menlo Park, California, USA 3 Department of Surgery, Stanford University School of Medicine, Stanford, California, USA 4 Department of Hematology & Oncology, UCLA Medical Center, Los Angeles, California, USA 5 Department of Pathology & Laboratory Medicine, UCLA Medical Center, Los Angeles, California, USA 6 Stanford Women’s Cancer Center, Stanford, California, USA 7 Division of Dermatology, UCLA Medical Center, Los Angeles, California, USA 8 California NanoSystems Institue, Los Angeles, California, USA 9 Jonsson Comprehensive Cancer Center, Los Angeles, California, USA Correspondence to: Dino Di Carlo, email: // Keywords : circulating tumor cells, immunofluorescent staining, rare cell enrichment, size based cell isolation, Vortex Received : January 18, 2016 Accepted : January 21, 2016 Published : February 06, 2016 Abstract Circulating tumor cells (CTCs) are emerging as rare but clinically significant non-invasive cellular biomarkers for cancer patient prognosis, treatment selection, and treatment monitoring. Current CTC isolation approaches, such as immunoaffinity, filtration, or size-based techniques, are often limited by throughput, purity, large output volumes, or inability to obtain viable cells for downstream analysis. For all technologies, traditional immunofluorescent staining alone has been employed to distinguish and confirm the presence of isolated CTCs among contaminating blood cells, although cells isolated by size may express vastly different phenotypes. Consequently, CTC definitions have been non-trivial, researcher-dependent, and evolving. Here we describe a complete set of objective criteria, leveraging well-established cytomorphological features of malignancy, by which we identify large CTCs. We apply the criteria to CTCs enriched from stage IV lung and breast cancer patient blood samples using the High Throughput Vortex Chip (Vortex HT), an improved microfluidic technology for the label-free, size-based enrichment and concentration of rare cells. We achieve improved capture efficiency (up to 83%), high speed of processing (8 mL/min of 10x diluted blood, or 800 μL/min of whole blood), and high purity (avg. background of 28.8±23.6 white blood cells per mL of whole blood). We show markedly improved performance of CTC capture (84% positive test rate) in comparison to previous Vortex designs and the current FDA-approved gold standard CellSearch assay. The results demonstrate the ability to quickly collect viable and pure populations of abnormal large circulating cells unbiased by molecular characteristics, which helps uncover further heterogeneity in these cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.7220

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Che, J., Yu, V., Dhar, M., Renier, C., Matsumoto, M., Heirich, K., Garon, E. B., Goldman, J., Rao, J., Sledge, G. W., Pegram, M. D., Sheth, S., Jeffrey, S. S., Kulkarni, R. P., Sollier, E., & Di Carlo, D.
Venue
Oncotarget
Published
2016-02-06
Volume
7
Issue
11
Pages
12748-12760
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2288173717
Cited by
177
References
0
FWCI
12.92
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.